Changshan Pharmaceutical (300255.SZ): There is still uncertainty about whether abenatide can finally be approved for marketing and when

According to the Zhitong Finance App, Changshan Pharmaceutical (300255.SZ) issued an announcement. The cumulative deviation value of the closing price increase of the company's shares exceeded 30% for two consecutive trading days (June 6, 2025 and June 9, 2025). According to the relevant regulations of the Shenzhen Stock Exchange, this is an abnormal fluctuation in stock trading. From May 6 to June 9, 2025, the cumulative increase in the company's stock price reached 147.69%. It has seriously deviated from the growth rate of the same industry and the GEM Composite Index. There is a situation where market sentiment is overheated, there may be irrational trading behavior, and there may be a risk that the company's stock price will fall after an irrational rise.

The company's epenatide injections have not yet been marketed. The company's marketing license application for epenatide injections for the treatment of type 2 diabetes has been accepted by the State Drug Administration. Currently, it is in the professional review stage. There are still many follow-up steps in the marketing review process for avenatide injections. There is still uncertainty about whether and when it will eventually be approved for marketing. There are many types of drugs to treat type 2 diabetes. GLP‑1RA is one of them, and many GLP‑1RA drugs have already been marketed or are being developed. Even if avenatide is marketed in the future, they face a high risk of market competition, and there is great uncertainty about the profit situation.

The company's clinical trial application for epenatide injections intended for weight loss has been accepted by the State Drug Administration. Currently, it is in the review stage, and there is uncertainty about whether a clinical trial approval notice can be obtained. Even if epenatide is approved to carry out clinical trial studies on weight loss indications, there are many uncertainties about the clinical trial progress and results, marketing review results, and future product market competition.

After verification, the company, controlling shareholders and actual controllers had no important matters relating to the company that should be disclosed but not disclosed, nor were there any undisclosed important matters relating to the company during the planning stage